A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

计划入组 132 人 · 首次发布于 2022 年 4 月 14 日

Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults

计划入组 240 人 · 首次发布于 2025 年 12 月 19 日

Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older

计划入组 390 人 · 首次发布于 2024 年 9 月 19 日

DT-preF

PIV3 vaccine(Vicebio)

DT-preF + adjuvant

Prof. Dr. Dirk Behringer

Germany

Prof. Dr. J. Steffens

Germany

Prof. Dr. med. Axel Ekkernkamp

Germany

Clover Reports Positive Phase 2 Data for RSV + hMPV ± PIV3 Combination Vaccines in Older Adults

Clover Biopharmaceuticals Reports Positive Phase I Data for First-in-Class RSV-hMPV-PIV3 Combination Vaccines

Clover Advances RSV Vaccine Program with FDA Clearance for Revaccination Trial